Imatinib as a potential treatment for sclerodermatous chronic graft-vs-host disease

Arch Dermatol. 2008 Sep;144(9):1106-9. doi: 10.1001/archderm.144.9.1106.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Benzamides
  • Chronic Disease
  • Graft vs Host Disease / drug therapy*
  • Graft vs Host Disease / etiology
  • Graft vs Host Disease / pathology
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery*
  • Male
  • Piperazines / therapeutic use*
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Scleroderma, Localized / drug therapy*
  • Scleroderma, Localized / etiology
  • Scleroderma, Localized / pathology

Substances

  • Benzamides
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Imatinib Mesylate